About Redoxis

Redoxis is a leading contract research organization specializing in preclinical drug development services. With a strong focus on inflammatory and autoimmune diseases, we provide high-quality in vitro and in vivo studies to support early-stage drug discovery and efficacy evaluation.

At Redoxis, we offer a broad range of expertise in different drug modalities, including small molecules, biologics, cell and gene therapies, and mRNA-based treatments. Our state-of-the-art laboratory facilities and dedicated team enable us to deliver reliable and reproducible data to accelerate the development of innovative therapeutics.

With a commitment to scientific excellence and customer collaboration, Redoxis partners with biotech and pharmaceutical companies worldwide. Our goal is to advance the development of next-generation treatments by providing reliable preclinical data and expert guidance throughout the drug discovery process.

Contact us to learn more about how Redoxis can support your research and drug development needs.

Customer Reviews

  • \"It has been a real pleasure to collaborate with Redoxis, a CRO that we have the greatest confidence in. Swift planning of projects, starts of experiments with a minimum of delay, very professional staff and thus high standard studies and rapid and excellent reports are important elements in the development of this good relation.\"

    Erik Walum, CEO

    Glucox Biotech, Sweden

  • \"I will like to place on record the very professional preparation of the protocol , conduct and preparation of the study report to our satisfaction.\"

    Bo Åkerström, Founder

    A1M Pharma, Sweden

  • \"Redoxis has been a valuable collaborator in our studies. Their expertise, reliability and effective study execution are an asset!\"

    Sushrusha Nayak, Manager Preclinical

    Chiesi

More Reviews

Contact us

Inquiries? Questions?

Nina Woodworth

COO